Current status of clinical trials of farnesyltransferase inhibitors

Current Opinion in Oncology

Volumn 13, Issue 6, 2001, Pages 470-476

  Karp, Judith E ^a   Kaufmann, Scott H ^b   Adjei, Alex A ^b   Lancet, Jeffrey E ^c   Wright, John J ^d   End, David W ^e  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LONAFARNIB; POLYPEPTIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER REGRESSION; CELL MATURATION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CHEEK MUCOSA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; GENE MUTATION; HUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

ALKYL AND ARYL TRANSFERASES; CLINICAL TRIALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; LEUKEMIA; NEOPLASMS; PIPERIDINES; PYRIDINES; QUINOLONES; SIGNAL TRANSDUCTION;

EID: 0034754072     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200111000-00009     Document Type: Review

References (53)

1. Drug development train gathering steam
2. Serine/threonine phosphorylation in cytokine signal transduction
3. Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies?
4. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway
5. Inhibition of purified Ras farnesyl: Protein transferase by Cys-AAX peptides
6. Cell growth inhibition by farnesyltransferase inhibitors is mediated by a gain of geranylgeranylated Rho B
7. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
8. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells
9. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
10. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
11. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with microtubules
12. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial
13. Multiple myeloma: Increasing evidence for a multistep transformation process
14. ras
15. Protein farnesyl transferase as a target for the development of anticancer agents
16. Protein prenylation: From discovery to prospects for cancer treatment
17. Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human xenograft models and wap-ras transgenic mice
18. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta [1,2-b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent
19. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
20. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biologic and clinical activity
21. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors
22. Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2-week on, 2-week off schedule
23. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
24. Phase I clinical and pharmacokinetic trials of the farnesyltransferase inhibitor R115777 in advanced cancer
25. Phase I and pharmacologic study of the novel farnesyltransferase inhibitor (FTI) R115777
26. A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced breast cancer
27. Farnesyltransferase inhibitors cause enhanced mitotic sensitivity to taxol and epithelones
28. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
29. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines
30. Phase I pharmacokinetic trial of the farnesyltransferase inhibitor SCH66336 plus gemcitabine in advanced cancers
31. Phase I study of farnesyltransferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
32. A phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (Herceptin) in patients with advanced cancer
33. A phase I and pharmacokinetic (PK) study of the farnesyltransferase inhibitor R115777 in combination with gemcitabine (Gem)
34. A phase I trial of the farnesyltransferase inhibitor R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer
35. A phase I, clinical and pharmacokinetic (PK) trial of the farnesyltransferase inhibitor (FTI) R115777 + Docetaxel: A promising combination in patients with solid tumors
36. A phase I pharmacokinetic and biologic study of the farnesyltransferase inhibitor (FTI) R115777 and capecitabine in patients with advanced solid malignancies
37. Essential role for oncogenic Ras I tumor maintenance
38. Myeloma cells with activated N-Ras are sensitive to FTI-277
39. Assays for inhibitors of CAAX farnesyl-transferase in vitro and in intact cells
40. Comparison of potential markers of farnesyltransferase inhibition
41. An antibody which specifically recognizes prelamin A but not mature lamin A: Application to detection of blocks in farnesylation-dependent protein processing
42. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers
43. The Hsp90 chaperone family
44. PxF, a prenylated protein of peroxisomes
45. Phase I trial of R115777, an oral farnesyltransferase (Ftase) inhibitor, in children with refractory solid tumors and neurofibromatosis type I (NF1)
46. Induction therapy with SCH66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck
47. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors
48. Resistance of a variant rastransformed cell line to phenotypic reversion by farnesyltransferase inhibitors
49. 1 pause in sensitive human tumor cell lines
50. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects
51. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo
52. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
53. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336